

Table 2. Demographics of Patients With Laboratory Monitoring<sup>a</sup>

Characteristic	Overall	Normal Laboratory Results or Laboratory Abnormality Prior to Therapy	Laboratory Abnormality During Therapy	P Value
Patients with laboratory monitoring, No. (%)	144 (54)	138 (96)	6 (4)	
Sex, No. (%)				
Female	68 (47)	65 (96)	3 (4)	.89
Male	76 (53)	73 (96)	3 (4)	
Age, No. (%), y				
<12	71 (49)	68 (96)	3 (4)	.97
≥12	73 (51)	70 (96)	3 (4)	

<sup>a</sup> Demographics of the study population and patients who underwent laboratory monitoring.  $\chi^2$  tests were performed to evaluate covariates of sex and age assuming a .05 significance level.

mild liver enzyme elevations are common postinfection. Clinically apparent liver injury from terbinafine treatment occurs in 1 per 50 000 to 120 000 cases.<sup>6</sup> Asymptomatic elevations in serum aminotransferases are found in less than 1% of patients, which typically self-resolve without discontinuing therapy.

We recommend baseline transaminase monitoring. However, routine laboratory monitoring during systemic therapy (12 weeks or less) for onychomycosis in healthy children may be unnecessary owing to low incidence of clinically significant adverse effects, costs of laboratory tests, workup of spurious laboratory abnormalities, and patient discomfort. This study is limited by its generalizability, small sample size, and retrospective nature. Larger, prospective studies evaluating the safety profile in pediatric patients are needed to detect the rare but serious adverse effects that could occur during therapy and work toward FDA label changes for a pediatric onychomycosis indication.

Deepa Patel, BS

Leslie A. Castelo-Soccio, MD, PhD

Adam I. Rubin, MD

Jenna L. Streicher, MD

**Author Affiliations:** University of Louisville, School of Medicine, Louisville, Kentucky (Patel); Department of Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Castelo-Soccio, Rubin, Streicher); Perelman School of Medicine, University of Pennsylvania, Philadelphia, (Castelo-Soccio, Rubin, Streicher); Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Rubin).

**Corresponding Author:** Jenna L. Streicher, MD, Section of Dermatology, Department of Pediatrics, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Wood Center, third Floor, Philadelphia, PA 19104 ([streicherj@email.chop.edu](mailto:streicherj@email.chop.edu)).

**Accepted for Publication:** September 16, 2017.

**Published Online:** November 29, 2017. doi:10.1001/jamadermatol.2017.4483

**Author Contributions:** Ms Patel and Dr Streicher had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** All authors.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Patel, Streicher.

**Critical revision of the manuscript for important intellectual content:** Castelo-Soccio, Rubin, Streicher.

**Statistical analysis:** Patel.

**Administrative, technical, or material support:** Castelo-Soccio, Rubin.

**Study supervision:** Castelo-Soccio, Rubin, Streicher.

**Conflict of Interest Disclosures:** None reported.

- Philpot CM, Shuttleworth D. Dermatophyte onychomycosis in children. *Clin Exp Dermatol*. 1989;14(3):203-205.
- Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. *Pediatr Dermatol*. 2013;30(3):316-322.
- Gupta AK, Paquet M. Systemic antifungals to treat onychomycosis in children: a systematic review. *Pediatr Dermatol*. 2013;30(3):294-302.
- Terbinafine hydrochloride [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
- National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03(CTCAE). [https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_5x7.pdf](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). Accessed May 15, 2017.
- National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Disease. Clinical and research information on drug-induced liver injury: drug record: terbinafine. <https://livertox.nlm.nih.gov/Terbinafine.htm>. Accessed May 15, 2017.

## The Most Beautiful People: Evolving Standards of Beauty

Not merely an aberration of modern culture, societal obsession with beauty is deeply engrained in the past, with the appreciation of human aesthetics dating back to early Greek civilization. Although ideas on beauty vary with personal preferences and cultural standards, in a society at any given time, there is substantial agreement as to what constitutes human beauty.<sup>1</sup> This study uses *People* magazine to compare standards of beauty in 1990 with present day standards.

**Methods** | Published by Time Inc, *People* has the largest audience of any US magazine, with a readership of 43.6 million adults.<sup>2</sup> We compared *People* magazine's World's Most Beautiful (WMB) list in the first issue (1990) with that in the 2017 issue, hypothesizing that beauty standards have not changed. From the 1990 (50 celebrities) and 2017 (135 celebrities) issues of *People* magazine's WMB list, we extracted the following information: age at the time of the specific issue, sex, race, skin type, hair color, eye color, and visible dermatologic conditions. Characteristics with dichotomous and categorical variables were reported as numbers (percentages) and continuous variables as means (SDs). Between-group differences were assessed using the Fisher exact test or  $\chi^2$  tests for categorical variables and *t* tests for continuous variables. Results were considered to be significant at  $P < .05$  in the 2-sided hypothesis. Institutional review board approval was waived by the Boston University Institutional Review Board. Because no patients were involved in this study, informed consent was not required.

**Table 1. Characteristics of the Celebrities Featured in *People's* 1990 and 2017 World's Most Beautiful Lists**

Characteristic	No. (%) of Celebrities (N = 185)
<b>Age, y</b>	
18-24	19 (10.3)
25-34	63 (34.1)
35-44	60 (32.4)
45-54	28 (15.1)
≥55	15 (8.1)
<b>Sex</b>	
Male	40 (21.6)
Female	145 (78.4)
<b>Race</b>	
White	119 (64.3)
Black	29 (15.7)
Asian	8 (4.3)
Hispanic	14 (7.6)
Mixed	15 (8.1)
<b>Fitzpatrick skin type</b>	
I	39 (21.1)
II	67 (36.2)
III	33 (17.8)
IV	14 (7.6)
V	28 (15.1)
VI	4 (2.2)
<b>Hair color</b>	
Blonde	37 (20.0)
Brown	143 (77.3)
Red	5 (2.7)
<b>Eye color</b>	
Blue	50 (27.0)
Brown	98 (53.0)
Green	19 (10.3)
Hazel	18 (9.7)
<b>Visible skin condition</b>	
Yes	5 (2.7)
No	180 (97.3)

**Results** | We compared 50 celebrities from the 1990 WMB list with 135 celebrities from the 2017 WMB list. Fitzpatrick skin types I to III represented 88.0% and Fitzpatrick skin types IV to VI represented 12.0% of the WMB list in 1990, whereas in 2017, Fitzpatrick skin types I to III represented 70.4% and Fitzpatrick skin types IV to VI represented 29.6% ( $P = .01$ ). Mean age increased; mean (SD) age was 33.2 (11.5) years in 1990 vs 38.9 (11.6) years in 2017 ( $P = .003$ ). The proportion of females also increased (26 [52.0%] in 1990 vs 119 [88.1%] in 2017;  $P < .001$ ), as did that of nonwhite races (12 [24.0%] in 1990 vs 54 [40.0%] in 2017;  $P = .04$ ). Those of mixed race were represented by 1 person (2.0%) in 1990 and 14 persons (10.4%) in 2017 ( $P = .07$ ). Only 5 of 185 (2.7%) had any visible skin condition or lesion that marred the even distribution of texture and/or color (Table 1 and Table 2).

**Discussion** | Human beauty is partially determined by a function of physical features, such as facial averageness, symme-

**Table 2. Comparison of Characteristics of the Celebrities Featured in *People's* 1990 and 2017 World's Most Beautiful Lists**

Characteristic	No. (%) of Celebrities		P Value <sup>a</sup>
	1990 (n = 50)	2017 (n = 135)	
<b>Age, y</b>			
18-24	8 (16.0)	11 (8.1)	.004
25-34	25 (50.0)	38 (28.1)	
35-44	12 (24.0)	48 (35.6)	
45-54	2 (4.0)	26 (19.3)	
≥55	3 (6.0)	12 (8.9)	
<b>Sex</b>			
Male	24 (48.0)	16 (11.9)	<.001
Female	26 (52.0)	119 (88.1)	
<b>Race</b>			
White	38 (76.0)	81 (60.0)	.04
Other	12 (24.0)	54 (40.0)	
<b>Fitzpatrick skin type</b>			
I-III	44 (88.0)	95 (70.4)	.01
IV-VI	6 (12.0)	40 (29.6)	
<b>Hair color</b>			
Blonde	6 (12.0)	31 (23.0)	.21
Brown	43 (86.0)	100 (74.1)	
Red	1 (2.0)	4 (3.0)	
<b>Eye color</b>			
Blue	14 (28.0)	36 (26.7)	.17
Brown	24 (48.0)	74 (54.8)	
Green	9 (18.0)	10 (7.4)	
Hazel	3 (6.0)	15 (11.1)	

<sup>a</sup> P values were generated using  $\chi^2$  or Fisher exact tests where appropriate.

try, skin homogeneity, and sexual dimorphism.<sup>3</sup> However, the perception of attractiveness is also influenced by more than these static physical characteristics. Ideals of beauty are often particular to the beholder and determined by the norms of a society, culture, or historical period.

As evidenced by our data and contrary to our hypothesis, at present, a wider variety of skin colors and inclusion of older age groups are represented among those deemed to be the most beautiful. Humans are a colorful species of primates, with the genetic palette allowing for wide variation in human skin, hair, and eye color.<sup>4</sup> In our study, skin types IV to VI were significantly more represented in 2017 than in 1990. The cosmetic industry has embraced this wide variety of complexions, producing varying hues of colors to complement rather than mask and hide inherent tone. The increase in mean age of the people featured in the WMB issue of *People*, with a significant increase in percentage of those 35 years and older, is significant in the present aging society.<sup>5</sup> According to the American Society for Dermatologic Surgery 2016 consumer report, 60% were considering a cosmetic procedure, and the top 3 reasons were to increase confidence, increase attractiveness, and look as young as they feel.<sup>6</sup>

The classic notion of beauty is a matter of mathematical conceptions and instantiating definite proportions. However, with the advent of the highly connected world that has

exposed individuals to many forms of beauty, we still strive to understand what beauty entails. The mass media platform has for years introduced certain criteria for what constitutes beauty. Through an examination of the WMB issue of *People*, we found that these beauty standards are evolving as people learn how to integrate the effects of media with exposure to new cultures and different norms.

Mayra B. C. Maymone, MD, DSc  
Hind H. Neamah, MD, MPH  
Eric A. Secemsky, MD, MSc  
Roopal V. Kundu, MD  
Dana Saade, MD  
Neelam A. Vashi, MD

**Author Affiliations:** Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts (Maymone, Neamah, Saade, Vashi); Department of Medicine, Massachusetts General Hospital, Boston (Secemsky); Harvard Medical School, Boston, Massachusetts (Secemsky); Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Kundu).

**Corresponding Author:** Neelam A. Vashi, MD, Department of Dermatology, Boston University School of Medicine, 609 Albany St, J108, Boston, MA 02118 (nvashi@bu.edu).

**Accepted for Publication:** August 1, 2017.

**Published Online:** October 11, 2017. doi:10.1001/jamadermatol.2017.3693

**Author Contributions:** Drs Vashi and Neamah had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

*Study concept and design:* Maymone, Vashi.

*Acquisition, analysis, or interpretation of data:* All authors.

*Drafting of the manuscript:* Maymone, Secemsky, Vashi.

*Critical revision of the manuscript for important intellectual content:* Neamah, Secemsky, Kundu, Saade, Vashi.

*Statistical analysis:* Neamah, Secemsky, Vashi.

*Obtained funding:* Vashi.

*Administrative, technical, or material support:* Maymone, Saade, Vashi.

*Study supervision:* Vashi.

**Conflict of Interest Disclosures:** None reported.

1. Hamermesh DS. *Beauty Pays: Why Attractive People Are More Successful*. Princeton, NJ: Princeton University Press; 2011.
2. Johnso-Greene C. AARP shows largest growth in readership. *Folio Magazine*. May 18, 2009. <http://www.foliomag.com/aarp-shows-largest-readership-growth-people-largest-audience/>. Accessed May 21, 2017.
3. Vashi N. *Beauty and Body Dysmorphic Disorder: A Clinician's Guide*. New York, NY: Springer International Publishing; 2015.
4. Jablonski NG, Chaplin G. The colours of humanity: the evolution of pigmentation in the human lineage. *Philos Trans R Soc Lond B Biol Sci*. 2017;372(1724):1-5.
5. Ortman J, Velkoff V, Hogan H. An aging nation: the older population in the United States: population estimates and projection. US Census Bureau website. May 2014. <https://www.census.gov/prod/2014pubs/p25-1140.pdf>. Accessed May 20, 2017.
6. ASDS Consumer survey on cosmetic procedures 2016. American Society for Dermatologic Surgery (ASDS) website. July 19, 2016. [https://www.asds.net/\\_Media.aspx?id=9576](https://www.asds.net/_Media.aspx?id=9576). Accessed May 21, 2017.

### Addressing Minority Representation in Dermatology: Answering a Call to Action Through Structured Mentorship and Instruction

Recent attention has been called to the insufficient representation in dermatology of African American and Hispanic individuals, which comprise the major populations underrepresented in medicine (UIM).<sup>1,2</sup> There have been 2 recent calls to

action to increase UIM populations in dermatology, a task that necessitates action.<sup>1,2</sup>

Among the numerous approaches previously suggested, mentoring and tutoring have been cited as some of the best to increase diversity.<sup>1,2</sup> We present the instructional and mentoring program we used to encourage UIM students in our community to consider dermatology careers in an attempt to show that even brief outreach programs can make a difference.

Table. Outline of Lectures, Activities, and Discussions in 4 Lessons

Session	Content
<b>Lesson 1</b>	
Introduction	Precurriculum survey
Discussion	What is a dermatologist?
Activity	Celebrities with dermatological conditions
Discussion	Resident Q&A
<b>Lesson 2</b>	
Lecture	Layers of the skin <ul style="list-style-type: none"> <li>Epidermis: layers, functions, Fitzpatrick skin types</li> <li>Dermis: functions, hair growth</li> <li>Subcutaneous fat: functions</li> </ul>
Lecture	Common skin, hair, and nail conditions <ul style="list-style-type: none"> <li>Acne vulgaris: types, pathogenesis, treatments, postinflammatory hyperpigmentation</li> <li>Vitiligo: pathogenesis</li> <li>Atopic dermatitis: pathogenesis, atopic triad</li> <li>Cutaneous T-cell lymphoma: mycosis fungoides, Sézary syndrome</li> <li>Traction alopecia: pathogenesis, prevention</li> <li>Pseudofolliculitis barbae: pathogenesis, risk factors, prevention</li> <li>Nail signs: pitting, clubbing, spoon shape, Hutchinson sign</li> </ul>
Activity	Classroom response system
<b>Lesson 3</b>	
Lecture	Skin cancer <ul style="list-style-type: none"> <li>Basal cell carcinoma: risk factors, types, dermoscopy, management</li> <li>Squamous cell carcinoma: risk factors, types</li> <li>Melanoma: risk factors, ABCDEs, types, management</li> <li>Sun protection: how to read sunscreen bottles, UV-A vs UV-B, sun-protective clothing</li> </ul>
Activity	Classroom response system
Activity	Biopsies and suturing <ul style="list-style-type: none"> <li>Videos: shave biopsy, punch biopsy, simple interrupted sutures</li> <li>Hands-on practice with biopsy and suture equipment</li> </ul>
<b>Lesson 4</b>	
Lecture	Vitamin D <ul style="list-style-type: none"> <li>Sun-induced synthesis</li> <li>Guidelines for supplementation</li> <li>How to maintain adequate stores</li> </ul>
Activity	Jeopardy <ul style="list-style-type: none"> <li>Categories: images, hair and nails, skin layers, sun and cancer, miscellaneous</li> </ul>
Wrap-up	Resident Q&A <ul style="list-style-type: none"> <li>Postcurriculum evaluation</li> </ul>

Abbreviations: ABCDEs, asymmetry, border, color, diameter, and evolution; Q&A, question and answer.